Human
We are now looking at Brockman’s other financial dealings.
Live updates from Elon Musk and Sam Altman’s court battle over the future of OpenAI
2 days ago
OpenAI’s courtroom drama took a sharp turn from lofty questions about AI’s future to the brass tacks of money, chips, and conflicts of interest — with president Greg Brockman’s wallet suddenly center stage.
From Microsoft “nothingburger” to something bigger
In testimony during the Musk v. Altman trial, the court first moved briskly past one of the biggest names in tech: Microsoft. The massive strategic investment by Microsoft in OpenAI — widely seen as a defining deal for the AI boom — was, in Brockman’s telling, not exactly his main concern.
“We finished with the Microsoft investment pretty quickly,” one live report summarized, noting that Brockman described the deal as “not really my focus area” and “kind of a nothingburger.” For a moment, the courtroom’s attention seemed to glide over one of the most consequential corporate marriages in AI history.
But what came next would prove harder to dismiss.
December 2025: A $10 billion chip deal
Attention turned to a different, more obscure but increasingly pivotal player in the AI arms race: Cerebras, a chip company building specialized hardware for training large AI models.
OpenAI, the court heard, struck a huge deal with Cerebras in December 2025 — a $10 billion commitment for AI chips. The transaction reportedly boosted Cerebras’s valuation to $23 billion. In any other context, that would simply be another staggering data point in the AI spend-a-thon.
In this courtroom, it landed differently — because Greg Brockman was not just OpenAI’s president. He was also an investor in Cerebras.
As summarized in the live coverage, the questioning zeroed in on the obvious point: “Your equity in Cerebras became more valuable because of the transaction OpenAI did?” Brockman, under oath, “admits that’s possible.”
That single acknowledgment crystallized the core tension: when a corporate leader helps steer a massive deal to a company he’s invested in, does that cross the line from good strategy to conflict of interest?
Peeling back the disclosures
The court did not stop at Cerebras. Reporters following the proceedings captured a key pivot: “We are now looking at Brockman’s other financial dealings.”
Those disclosures painted a broader pattern. Brockman held stakes in multiple companies that weren’t just random startups — they were all entangled in OpenAI’s business. “Cerebras, Stripe, CoreWeave, and Helion all appear on his financial disclosures. All four have deals with OpenAI.”
What emerged was less a one-off coincidence and more a network of overlapping interests:
- Cerebras — chip supplier to OpenAI, beneficiary of the $10 billion deal.
- Stripe — a critical payments infrastructure player, with integrations and commercial ties across the AI economy.
- CoreWeave — a fast-rising GPU cloud provider competing to power AI workloads.
- Helion — a fusion energy company backed by Microsoft and others, betting on the energy-hungry future of AI.
The live blog coverage captured the creeping realization in the room: “I see where this is going — probably a preview of what to expect with Altman.”
In other words, Brockman’s portfolio might just be the overture to a much larger inquiry into how OpenAI’s top leadership stands to benefit personally from the ecosystem of companies orbiting its meteoric rise.
The timeline: how the pieces line up
Putting the fragments together, a chronological picture forms:
-
Pre-2025 — Brockman builds a substantial personal portfolio, investing in Cerebras, Stripe, CoreWeave, and Helion — all companies that either already have or later develop business relationships with OpenAI.
-
Microsoft investment (prior to or around 2025) — OpenAI’s defining partnership with Microsoft is finalized. In court, this episode is dispatched quickly; Brockman characterizes it as outside his main focus and “kind of a nothingburger” from his perspective.
-
December 2025 — The Cerebras deal — OpenAI signs a $10 billion chip deal with Cerebras, lifting the company’s valuation to $23 billion. Brockman is already an investor in Cerebras, and concedes on the stand that his equity likely became more valuable due to the transaction.
-
May 2026 — Musk v. Altman trial turns to conflicts — During the trial, lawyers and the court dive into Brockman’s personal holdings, linking them to OpenAI’s major commercial decisions. Reporters note that digging into Brockman’s disclosures “probably [offers] a preview of what to expect with Altman,” signaling that the same scrutiny will likely be applied to the CEO’s financial web.
One set of facts, clashing narratives
The raw facts are not really in dispute: Brockman invested in multiple companies that do business with OpenAI; OpenAI executed a massive chip deal that likely enhanced the value of one of those holdings; and he acknowledges that this is plausible.
Where perspectives diverge is on what those facts mean.
The defense: strategic ecosystem, not self-dealing
From one vantage point — particularly the defense’s — what’s being painted as conflict could be reframed as alignment.
Brockman is a central architect of the AI boom. Investing in critical infrastructure players like Cerebras, CoreWeave, and Helion can be cast as a logical expression of conviction: he bet his own money on the very technologies he believes OpenAI needs to succeed.
In that telling, the $10 billion Cerebras deal is not a backdoor enrichment scheme but a strategic necessity. The AI arms race is constrained by chips; whoever secures capacity wins. OpenAI locking in a long-term supply of specialized hardware looks like aggressive, perhaps essential, execution.
Brockman’s offhand dismissal of the Microsoft deal as “not really my focus area” reinforces a portrait of an operator obsessed with technology and infrastructure rather than machinating around cap tables and exit multiples.
The critics: a textbook conflict-of-interest pattern
From the opposing perspective, that same set of facts looks like a red flag marathon.
Start with the structure: an executive with significant influence over procurement and strategic direction holds stakes in companies that are — or soon become — vendors and partners. Then, one of those firms receives a colossal $10 billion contract, inflating its valuation to $23 billion.
Add Brockman’s on-the-record concession that it’s “possible” his equity became more valuable because of a decision OpenAI made under his leadership. That’s the very definition of a potential conflict of interest: a corporate decision that could personally enrich the decision-maker.
The broader pattern deepens the suspicion. Cerebras, Stripe, CoreWeave, and Helion don’t just pop up randomly on a disclosure form; all four “have deals with OpenAI.” For critics, that’s not ecosystem alignment — it’s a cluster of overlapping incentives that should have triggered stricter governance, recusals, or independent review.
And the ominous line from the live blog — “I see where this is going — probably a preview of what to expect with Altman” — suggests that scrutiny of Brockman is seen less as an isolated case and more as a window into how OpenAI’s leadership may have been allowed to blur the line between personal and institutional gain.
Why this matters beyond the courtroom
This showdown lands at a delicate moment. OpenAI is not just a startup anymore; it sits atop a stack of products, partnerships, and policies that shape how AI enters the mainstream.
If its top executives are perceived as using their positions to juice their private stakes — even legally, even “only possibly” — it chips away at the public narrative that OpenAI is a mission-driven steward of a world-transforming technology.
The courtroom drama is therefore about more than one December 2025 contract. It is about whether the people steering AI’s trajectory are making decisions in the public interest, in the company’s interest — or in their own.
With Brockman’s portfolio now laid out and the Cerebras deal under the microscope, the subtext of the trial is clear: if this is just the “preview,” the feature-length scrutiny of Sam Altman’s financial entanglements could redefine how OpenAI — and the entire AI industry — is governed.